AbbVie's hepatitis C regimen Viekirax, Exviera achieves 100 percent cure rate in genotype 1b patients

AbbVie on Wednesday announced that its all-oral ribavirin-free hepatitis C regimen of Viekirax (ombitasvir/paritaprevir/ritonavir) and Exviera (dasabuvir) achieved a sustained virologic response rate at 12 weeks (SVR12) of 100 percent in patients with genotype 1b chronic hepatitis C and compensated liver cirrhosis. Results from the Phase IIIb trial are scheduled to be presented at the upcoming Annual International Symposium on Viral Hepatitis and Liver Diseases.

In the TURQUOISE-III study, 60 adult patients with genotype 1b chronic hepatitis C and compensated liver cirrhosis, including both treatment-naïve and treatment-experienced patients, were treated with Viekirax and Exviera for 12 weeks to assess the safety and efficacy of the regimen. The primary endpoint of the study was SVR12. (press release)

AbbVie noted that in addition to the absence of virologic failure during treatment, no patient experienced relapse following treatment discontinuation. The drugmaker added that no patient required treatment discontinuation due to adverse events, while the most commonly observed adverse events included fatigue, diarrhoea and headache.

The combination of Viekirax and Exviera was cleared by regulators in Europe last January for the treatment of patients with genotype 1 chronic hepatitis C virus infection with or without ribavirin, following its approval in the US under the name Viekira Pak and its authorisation in Canada under the name Holkira Pak.

To read more Top Story articles, click here.